Abstract 20207: Lower Risk in Young Patients Aged < 50 With Atrial Fibrillation and Low CHA2DS2-VASc Risk Score

Laurent Fauchier; Arnaud Bisson; Nicolas Clémenty; Denis Angoulvant; Dominique Babuty; Professor Gregory Lip; Ben Freedman

Abstract

1 min read

It is unclear whether oral anticoagulants (OAC) are beneficial for patients with atrial fibrillation (AF) at intermediate stroke risk i.e. CHA2DS2-VASc score of 1 (male) or 2 (female), and whether ...

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2017

Abstract 20207: Lower Risk in Young Patients Aged < 50 With Atrial Fibrillation and Low CHA2DS2-VASc Risk Score

Laurent Fauchier, Arnaud Bisson, Nicolas Clémenty, Denis Angoulvant, Dominique Babuty, Professor Gregory Lip, Ben Freedman

Article2017

Abstract 20207: Lower Risk in Young Patients Aged < 50 With Atrial Fibrillation and Low CHA2DS2-VASc Risk Score

Laurent Fauchier, Arnaud Bisson, Nicolas Clémenty, Denis Angoulvant, Dominique Babuty, Professor Gregory Lip, Ben Freedman

Article2020

Thromboembolic risk in non-anticoagulated atrial fibrillation patients with valvular heart disease and low CHA2DS2-VASc scores: are these patients truly low risk of stroke?

Line Melgaard, Thure Filskov Overvad, Martin Jensen, Professor Gregory Lip, Torben Bjerregaard Larsen, Peter Brønnum Nielsen

Article2020

Anticoagulant Therapy in Initially Low‐Risk Patients With Nonvalvular Atrial Fibrillation Who Develop Risk Factors

Sun Young Choi, Moo Hyun Kim, Kwang Min Lee, Young‐Rak Cho, Jong Sung Park, Seong Woo Kim, Jin Kyung Kim, Matthew Chung, Sung‐Cheol Yun, Professor Gregory Lip

Article2016

Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA <sub>2</sub> DS <sub>2</sub> -VASc Score 1 in Men, 2 in Women) Be Anticoagulated?

Professor Gregory Lip, Peter Brønnum Nielsen